In a deal that both partners cited as "transformative" for their companies and for the field of immunotherapeutics, Celgene Corp. enlisted Juno Therapeutics Inc. as a partner in a broad, global collaboration to leverage T-cell therapies and develop treatments targeting cancer and autoimmune diseases. Read More
Executives at Amag Pharmaceuticals Inc. were already hinting at future acquisitions on Monday's conference call even as investors were digesting news of the $700 million cash purchase of Cord Blood Registry (CBR), a newborn stem cell collection and storage firm. Read More
Of the many types of evidence that a protein might make a good drug target, human genetic studies linking its gene to the disease being targeted is considered one of the better ones. Read More
As a paper last month in Nature predicted a "bumpy road" ahead for RNA polymerase II research, pointing to an "additional level of complexity" that has turned up in the work, Pharmamar SA – bolstered by impressive phase II results – forged ahead with the phase III experiment testing PM1183 (lurbinectedin) in patients with platinum-resistant ovarian cancer (PROC). Read More
A type 2 diabetes drug discovered by Vitae Pharmaceuticals Inc. and partnered with Boehringer Ingelheim GmbH failed to meet Boehringer's primary efficacy endpoint – change in fasting plasma glucose – when combined with the common diabetes medicine metformin in an ongoing phase II study. Read More
While lawmakers debate how to correct the unintended consequences of the America Invents Act, more drug- and device-makers risk being held up by reverse patent trolls threatening to challenge their patents through the Patent and Trademark Office's inter partes review (IPR) process. Read More
NEW DELHI – India has launched a pharmaceutical price databank to be managed and operated by its drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), to help consumers make informed product formulation and rate choices. Read More
Zosano Pharma Corp., of Fremont, Calif., said it amended its existing secured-term loan facility with Hercules Technology Growth Capital, Inc. and obtained $15 million in debt financing, with an approximately $11.7 advance made at closing of the loan amendment. Read More
strong>Amarna Therapeutics BV, of Leiden, the Netherlands, said it entered a cooperation with Austrian Center for Biomarker Research in Medicine (CBmed) for the development of immunotherapies against acute lymphoblastic leukemia (ALL), obesity, type 2 diabetes and atherosclerotic cardiovascular disease. Read More
Biondvax Pharmaceuticals Ltd., of Ness Ziona, Israel, reported positive preliminary results from its BVX-006 phase II trial of M-001, a universal influenza vaccine. Read More
